Understanding how a specific protein affects brain development in primates
Interrogate FMRP functions in primate brain development
['FUNDING_R01'] · UNIVERSITY OF WISCONSIN-MADISON · NIH-11081052
This study is looking at how a specific protein called FMRP affects brain development in primates, which could help us understand more about Fragile X Syndrome and autism, ultimately aiming to improve treatments for these conditions.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WISCONSIN-MADISON (nih funded) |
| Locations | 1 site (MADISON, UNITED STATES) |
| Trial ID | NIH-11081052 on ClinicalTrials.gov |
What this research studies
This research investigates the role of Fragile X Messenger Ribonucleoprotein 1 (FMRP) in brain development, particularly in the prefrontal cortex of primates. By examining how FMRP functions in the primate brain, the study aims to uncover mechanisms that contribute to Fragile X Syndrome (FXS) and autism spectrum disorders (ASD). The research utilizes advanced techniques to analyze gene expression and protein interactions, providing insights that could lead to better understanding and treatment of these conditions. This work is crucial as previous studies primarily relied on rodent models, which may not fully represent human brain development.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Fragile X Syndrome or autism spectrum disorders, particularly those who are 21 years old or younger.
Not a fit: Patients without a diagnosis of Fragile X Syndrome or autism spectrum disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and potential new treatments for individuals affected by Fragile X Syndrome and autism spectrum disorders.
How similar studies have performed: While research on FMRP has been conducted in rodent models, this approach using primate models is relatively novel and aims to address gaps in understanding FXS and ASD.
Where this research is happening
MADISON, UNITED STATES
- UNIVERSITY OF WISCONSIN-MADISON — MADISON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHAO, XINYU — UNIVERSITY OF WISCONSIN-MADISON
- Study coordinator: ZHAO, XINYU
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: autism spectral disorder, autism spectrum disorder, autism-fragile X (AFRAX) syndrome, Autistic Disorder, autistic spectrum disorder